BioAtla to Participate in the Citizens JMP Life Sciences Conference
BioAtla, Inc. (BCAB)
Company Research
Source: GlobeNewswire
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024. Format: Fireside chat and scheduled one-on-one investor meetingsDate: Monday, May 13, 2024Time: 9:30 a.m. ETLocation: New York, NYWebcast Link: Click Here About BioAtla®, Inc.BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific an
Show less
Read more
Impact Snapshot
Event Time:
BCAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAB alerts
High impacting BioAtla, Inc. news events
Weekly update
A roundup of the hottest topics
BCAB
News
- BioAtla, Inc. (NASDAQ: BCAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress [Yahoo! Finance]Yahoo! Finance
- BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent ProgressGlobeNewswire
- BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024GlobeNewswire
- BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors [Yahoo! Finance]Yahoo! Finance
BCAB
Earnings
- 5/14/24 - Beat
BCAB
Sec Filings
- 5/17/24 - Form 8-K
- 5/14/24 - Form 10-Q
- 5/14/24 - Form 8-K
- BCAB's page on the SEC website